PubMed:32838169
Annnotations
LitCovid_Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 432-439 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T2 | 432-439 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
| T3 | 1218-1225 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | Heparin |
| T4 | 1218-1225 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | Heparin |
| T5 | 1539-1546 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | Heparin |
| T6 | 1539-1546 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | Heparin |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T1 | 432-439 | Body_part | denotes | heparin | http://purl.org/sig/ont/fma/fma82839 |
| T2 | 1218-1225 | Body_part | denotes | Heparin | http://purl.org/sig/ont/fma/fma82839 |
| T3 | 1539-1546 | Body_part | denotes | Heparin | http://purl.org/sig/ont/fma/fma82839 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T1 | 180-188 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T2 | 316-324 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T3 | 624-632 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T4 | 725-733 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T5 | 1275-1283 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T6 | 1380-1388 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T7 | 1600-1608 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 163-168 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T2 | 277-282 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | human |
| T3 | 1519-1525 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | tested |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T1 | 356-375 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T2 | 356-365 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T3 | 366-375 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T4 | 377-384 | Chemical | denotes | arbidol | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T5 | 386-404 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T6 | 406-417 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T7 | 419-430 | Chemical | denotes | favipiravir | http://purl.obolibrary.org/obo/CHEBI_134722 |
| T8 | 432-439 | Chemical | denotes | heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
| T9 | 445-458 | Chemical | denotes | dexamethasone | http://purl.obolibrary.org/obo/CHEBI_41879 |
| T10 | 552-561 | Chemical | denotes | Lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T11 | 562-571 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T12 | 918-937 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T13 | 918-927 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T14 | 928-937 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T15 | 1008-1027 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T16 | 1008-1017 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T17 | 1018-1027 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T18 | 1029-1036 | Chemical | denotes | arbidol | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T19 | 1038-1056 | Chemical | denotes | hydroxychloroquine | http://purl.obolibrary.org/obo/CHEBI_5801 |
| T20 | 1061-1071 | Chemical | denotes | remdesivir | http://purl.obolibrary.org/obo/CHEBI_145994 |
| T21 | 1185-1204 | Chemical | denotes | lopinavir/ritonavir | http://purl.obolibrary.org/obo/CHEBI_145924 |
| T22 | 1185-1194 | Chemical | denotes | lopinavir | http://purl.obolibrary.org/obo/CHEBI_31781 |
| T23 | 1195-1204 | Chemical | denotes | ritonavir | http://purl.obolibrary.org/obo/CHEBI_45409 |
| T24 | 1209-1216 | Chemical | denotes | arbidol | http://purl.obolibrary.org/obo/CHEBI_134730 |
| T25 | 1218-1225 | Chemical | denotes | Heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
| T26 | 1230-1243 | Chemical | denotes | dexamethasone | http://purl.obolibrary.org/obo/CHEBI_41879 |
| T27 | 1539-1546 | Chemical | denotes | Heparin | http://purl.obolibrary.org/obo/CHEBI_28304 |
| T28 | 1551-1564 | Chemical | denotes | dexamethasone | http://purl.obolibrary.org/obo/CHEBI_41879 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-77 | Sentence | denotes | Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials. |
| T2 | 78-206 | Sentence | denotes | The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. |
| T3 | 207-325 | Sentence | denotes | An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. |
| T4 | 326-459 | Sentence | denotes | Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. |
| T5 | 460-551 | Sentence | denotes | Statistical analyses were performed for common viral clearance endpoints whenever possible. |
| T6 | 552-668 | Sentence | denotes | Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50-1.83]). |
| T7 | 669-785 | Sentence | denotes | Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80-5.84]). |
| T8 | 786-938 | Sentence | denotes | Arbidol showed no 7-day (OR 1.63 [95% CI 0.76-3.50]) or 14-day viral (OR 5.37 [95% CI 0.35-83.30]) clearance difference compared to lopinavir/ritonavir. |
| T9 | 939-1072 | Sentence | denotes | Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. |
| T10 | 1073-1125 | Sentence | denotes | Tocilizumab showed mixed results regarding survival. |
| T11 | 1126-1217 | Sentence | denotes | Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. |
| T12 | 1218-1325 | Sentence | denotes | Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. |
| T13 | 1326-1411 | Sentence | denotes | Current medications do not show significant effect on COVID-19 viral clearance rates. |
| T14 | 1412-1464 | Sentence | denotes | Tocilizumab showed mixed results regarding survival. |
| T15 | 1465-1538 | Sentence | denotes | Favipiravir shows favorable results compared to other tested medications. |
| T16 | 1539-1615 | Sentence | denotes | Heparin and dexamethasone show benefit especially for severe COVID-19 cases. |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1 | 37-59 | Disease | denotes | Coronavirus Disease 19 | MESH:C000657245 |
| 36 | 163-168 | Species | denotes | human | Tax:9606 |
| 37 | 180-188 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 38 | 277-282 | Species | denotes | human | Tax:9606 |
| 39 | 316-324 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 40 | 356-375 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 41 | 377-384 | Chemical | denotes | arbidol | MESH:C086979 |
| 42 | 386-404 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 43 | 406-417 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 44 | 419-430 | Chemical | denotes | favipiravir | MESH:C462182 |
| 45 | 432-439 | Chemical | denotes | heparin | MESH:D006493 |
| 46 | 445-458 | Chemical | denotes | dexamethasone | MESH:D003907 |
| 47 | 552-571 | Chemical | denotes | Lopinavir/ritonavir | MESH:C558899 |
| 48 | 624-632 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 49 | 669-687 | Chemical | denotes | Hydroxychloroquine | MESH:D006886 |
| 50 | 725-733 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 51 | 786-793 | Chemical | denotes | Arbidol | MESH:C086979 |
| 52 | 918-937 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 53 | 1008-1027 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 54 | 1029-1036 | Chemical | denotes | arbidol | MESH:C086979 |
| 55 | 1038-1056 | Chemical | denotes | hydroxychloroquine | MESH:D006886 |
| 56 | 1061-1071 | Chemical | denotes | remdesivir | MESH:C000606551 |
| 57 | 1073-1084 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 58 | 1126-1137 | Chemical | denotes | Favipiravir | MESH:C462182 |
| 59 | 1185-1204 | Chemical | denotes | lopinavir/ritonavir | MESH:C558899 |
| 60 | 1209-1216 | Chemical | denotes | arbidol | MESH:C086979 |
| 61 | 1218-1225 | Chemical | denotes | Heparin | MESH:D006493 |
| 62 | 1230-1243 | Chemical | denotes | dexamethasone | MESH:D003907 |
| 63 | 1275-1283 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 64 | 1380-1388 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 65 | 1412-1423 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 66 | 1465-1476 | Chemical | denotes | Favipiravir | MESH:C462182 |
| 67 | 1539-1546 | Chemical | denotes | Heparin | MESH:D006493 |
| 68 | 1551-1564 | Chemical | denotes | dexamethasone | MESH:D003907 |
| 69 | 1600-1608 | Disease | denotes | COVID-19 | MESH:C000657245 |